Health At Every Size and Acceptance and Commitment Therapy vs. Behavioral Weight Loss for Obesity and Depression in Women
Health At Every Size and Acceptance and Commitment Therapy vs. Behavioral Weight Loss for Obesity and Depression in Women: A Randomized Controlled Trial
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
New Hampshire
-
Lebanon, New Hampshire, Stati Uniti, 03766
- Dartmouth-Hitchcock Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- English-speaking
- Major Depressive Disorder (assessed using the Structured Clinical Interview for DSM-IV, SCID-IV)
- Body Mass Index (BMI) greater than or equal to 30
- Not taking medications or on stable medication regimens (i.e. no medication changes for six weeks prior to enrollment or during the study)
Exclusion Criteria:
- current substance dependence
- history of psychotic symptoms
- high risk of suicide/self-harm
- current enrollment in a weight-loss program
- weight loss surgery in the past year
- current psychotherapy
- inability to postpone weight loss or depression treatment interventions for the duration of the study
- taking antipsychotic, tricyclic, or oral corticosteroid medication
- unwilling to be randomized to the study treatments
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Accept Yourself! Intervention
Combined Health At Every Size and Acceptance and Commitment Therapy Psychotherapy Group
|
Altri nomi:
|
|
Comparatore attivo: Behavioral Weight Loss
Weight Watchers groups
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in clinician assessed depression symptoms
Lasso di tempo: At post-treatment (immediately following the three-month intervention) and at 3, 6, 9, and 12-month follow-up assessments.
|
As assessed by clinician rated Hamilton Depression Rating Scale (HAM-D)
|
At post-treatment (immediately following the three-month intervention) and at 3, 6, 9, and 12-month follow-up assessments.
|
|
Change in self-reported depression symptoms
Lasso di tempo: At post-treatment (immediately following the three-month intervention) and at 3, 6, 9, and 12-month follow-up assessments.
|
As assessed by Patient Health Questionnaire-9 (PHQ-9)
|
At post-treatment (immediately following the three-month intervention) and at 3, 6, 9, and 12-month follow-up assessments.
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in fasting Lipids
Lasso di tempo: At post-treatment (immediately following the three-month intervention) and at 12 month follow-up.
|
At post-treatment (immediately following the three-month intervention) and at 12 month follow-up.
|
|
|
Change in systolic and diastolic blood pressure
Lasso di tempo: At post-treatment (immediately following the three-month intervention) and 12 month follow up
|
At post-treatment (immediately following the three-month intervention) and 12 month follow up
|
|
|
Change in fasting blood glucose
Lasso di tempo: At post-treatment (immediately following the three-month intervention) and 12 month follow up
|
At post-treatment (immediately following the three-month intervention) and 12 month follow up
|
|
|
Change in eating disorder symptoms, measured by the Eating Disorders Diagnostic Scale (EDDS)
Lasso di tempo: At post-treatment (immediately following the three-month intervention) and at 3, 6, 9, and 12-month assessments.
|
At post-treatment (immediately following the three-month intervention) and at 3, 6, 9, and 12-month assessments.
|
|
|
Change in obesity-related quality of life, measured by the Obesity-Related Well-Being Questionnaire (ORWELL97)
Lasso di tempo: At post-treatment (immediately following the three-month intervention) and at 3, 6, 9, and 12-month assessments.
|
At post-treatment (immediately following the three-month intervention) and at 3, 6, 9, and 12-month assessments.
|
|
|
Change in obesity stigma, measured by the Weight Self-Stigma Questionnaire (WSSQ)
Lasso di tempo: At post-treatment (immediately following the three-month intervention) and at 3, 6, 9, and 12-month assessments.
|
At post-treatment (immediately following the three-month intervention) and at 3, 6, 9, and 12-month assessments.
|
|
|
Number of participants who did not complete an adequate dose of the intervention (at least 7 group visits)
Lasso di tempo: At post-treatment (immediately following the three-month intervention)
|
At post-treatment (immediately following the three-month intervention)
|
|
|
Change in weight
Lasso di tempo: At post-treatment (immediately following the three-month intervention) and 12 month follow up
|
Note that we are assessing weight change primarily as a safety measure (i.e., to demonstrate no significant weight gain in intervention group).
|
At post-treatment (immediately following the three-month intervention) and 12 month follow up
|
|
Change in self-reported physical activity
Lasso di tempo: At post-treatment (immediately following the three-month intervention) and at 12-month follow-up.
|
At post-treatment (immediately following the three-month intervention) and at 12-month follow-up.
|
|
|
Change in cardiovascular fitness as assessed by six-minute walk test
Lasso di tempo: At post-treatment (immediately following the three-month intervention) and at 12-month follow-up.
|
At post-treatment (immediately following the three-month intervention) and at 12-month follow-up.
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Margit I Berman, Ph.D, Dartmouth College
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- D15151
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Accept Yourself!
-
NCT04936100CompletatoCecità | Compromissione della vista
-
NCT06212219Reclutamento